Smith & Nephew rating upgraded to “buy” — 5 things to know

Smith & Nephew was upgraded to a “buy” rating by equities research analysts at Goldman Sachs, according to a Dakota Financial News report.

Advertisement

Here are five things to know about the company’s stock:

 

•    Goldman Sachs upgraded Smith & Nephew from a “neutral” rating.
•    Smith & Nephew has a one-year low of $28.87 and a one-year high of $40.38.
•    The stock’s 50-day moving average is $35 and its 200-day moving average is $34.
•    The company has a market cap of $15.32 billion.
•    Currently, the stock has an average rating of “hold” and an average price target of $63.30.

More articles on devices:
10 things to know about the PRP market through 2020
Zimmer CEO sells stock in $150k transaction — 5 key notes
John Dahldorf becomes new Benvenue Medical CFO — 5 key notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.